Manufacturer
KOTRA PHARMA (M) SDN. BHD.
Contents
Chloroquine Phosphate 250mg equivalent to Chloroquine Base 155mg
Indication
Prophylaxis and treatment of malaria, amoebic hepatitis and liver abscess, giardiasis, rheumatoid arthritis and lupus erythematosus.
Instruction
Should be taken with food.
Drug interaction
Concomitant therapy with phenylbutazone predisposes to dermatitis, antagonises effect of neostigmine and pyridostigmine, reduces bioavailability of ampicillin. Cimetidine inhibits metabolism of chloroquine raising plasma levels. Potentially Fatal: Increased risks of inducing ventricular arrhythmias with halofantrine or other arrhythmogenic drugs eg, amiodarone. Increased risk of convulsions with mefloquine. Antacids reduce absorption of chloroquine hence admin should be separated by 4 hrs. Rarely Stevens-Johnson syndrome, when administered with pyrimethamine/sulphadoxine. Increased toxicity with quinacrine.